Peptide based Drug Delivery Strategy
Joon Hwang Ph.D.
Peptide-based drugs are gaining attention as a key next-generation therapeutic modality, capable of overcoming the significant side-effect risks associated with conventional small-molecule drugs, as well as the high manufacturing costs and limited cell permeability inherent in antibody-based (protein) therapeutics. Peptides—fragments consisting of approximately 2 to 50 amino acids—offer unique advantages that address the shortcomings of existing medical treatments, leading to a rapidly growing demand for them in modern medicine.
1. High Safety and Low Side Effects (High Biocompatibility)
Similarity to Endogenous Substances: Peptides are composed of amino acids—the building blocks of the human body—and are therefore naturally broken down through the body’s metabolic processes.
Minimized Toxicity: Unlike chemically synthesized drugs (small-molecule compounds), peptides leave virtually no toxic residues in the liver or kidneys, resulting in a significantly lower risk of side effects.
2. Excellent Target Specificity (High Efficacy)
Precision Targeting: Peptides possess an exceptional ability to bind precisely to specific disease-causing agents (target proteins).
Maximized Effectiveness: By acting exclusively on the intended targets without affecting surrounding healthy cells, peptides can deliver high therapeutic efficacy even at low doses.
3. Addressing Unmet Medical Needs
Treatment for Intractable Diseases: Peptides can effectively modulate protein-protein interactions (PPIs)—a challenging area for traditional drug development. They serve as an essential alternative for treating chronic or hard-to-treat conditions, such as cancer, autoimmune disorders, and neurodegenerative diseases.
Key Driver in the Obesity and Metabolic Disease Market: The widely popular GLP-1 receptor agonist class of drugs—used for treating obesity and diabetes—are prominent examples of peptide-based therapeutics.
4. Greater Cost-Efficiency and Ease of Development Compared to Antibody-Based Drugs
Reduced Production Costs: Large proteins and antibody-based therapeutics require complex, expensive bioprocessing (such as cell culture). In contrast, peptides have a relatively smaller molecular weight, making them easier to synthesize chemically and more cost-effective to produce on a large scale.
To overcome the major drawbacks of peptides—namely their tendency to degrade too rapidly within the body (short half-life) and the inconvenience of requiring administration solely via injection—there is active research into drug delivery systems (DDS) aimed at extending the duration of therapeutic effect or enabling oral administration.
Peptide based drug delivery bioavailability is unsolved problem as a science and technology
The bioavailability of peptide drug delivery remains a significant scientific and technical challenge. Due to rapid enzymatic degradation and low membrane permeability, the systemic oral bioavailability of peptides is less than 1%.
1. Biological and chemical barriers resulting from the complexity of the gastrointestinal (GI) tract
Enzymatic degradation: Digestive enzymes in the GI tract—such as pepsin, trypsin, and chymotrypsin—break down peptide bonds prior to absorption.
Epithelial permeability: Peptides are typically large, hydrophilic, and charged molecules, making it difficult for them to pass through lipophilic cell membranes and dense mucus layers.
First-pass metabolism: Molecules that successfully cross the GI barrier are rapidly cleared and metabolized by the liver before reaching systemic circulation.
Peptide therapeutics are emerging as a rapidly growing class of drugs, characterized by their high specificity and ability to modulate molecular targets that were previously considered difficult to address.
To maximize the clinical and commercial potential of these therapies—particularly for chronic diseases—patient-friendly routes of administration are essential; among these, oral delivery is often preferred due to its non-invasive nature. However, peptides frequently possess physicochemical properties that hinder epithelial permeability, such as high polarity, electrical charge, large molecular size, and instability against proteolytic degradation. The combined effect of these factors often results in low or insufficient systemic bioavailability.
Recent advancements in peptide chemistry are transforming the landscape of oral administration. Through structural modifications that enhance efficacy, metabolic stability, and half-life—as demonstrated by successful late-stage clinical candidates—it has become possible to achieve therapeutic effects even with low, single-digit oral bioavailability. Consequently, the primary challenge is no longer a question of feasibility, but rather the design of mechanistically optimized formulation strategies tailored to the specific physicochemical and pharmacokinetic properties of individual peptides.